上海妙道企业管理咨询有限公司 独立财务顾问报告 关于 圣湘生物科技股份有限公司 2025 年限制性股票激励计划 授予相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二五年八月 1 上海妙道企业管理咨询有限公司 一、本独立财务顾问报告所依据的文件、材料由圣湘生物提供，圣湘生物 已向本独立财务顾问承诺：其所提供的有关本激励计划的相关信息真实、准确 和完整，保证该等信息不存在虚假记载、误导性陈述或者重大遗漏。 二、本独立财务顾问本着勤勉、审慎、对上市公司全体股东尽责的态度， 依据客观公正的原则，对本激励计划事项进行了尽职调查义务，有充分理由确 信所发表的专业意见与上市公司披露的文件内容不存在实质性差异，并对本独 立财务顾问报告的真实性、准确性和完整性承担责任。 | 第一章 | 声 明 | 3 | | --- | --- | --- | | 第二章 | 释 义 | 5 | | 第三章 | 基本假设 | 7 | | 第四章 | | 本激励计划履行的审批程序 8 | | 第五章 | | 本次限制性股票的授予情况 10 | | | | 一、限制性股票授予的具体情况 10 | | | | 二、本次实施的股权激励计划与股东 ...

西部证券股份有限公司 关于圣湘生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 西部证券股份有限公司（以下简称"保荐人"）作为圣湘生物科技股份有限 公司（以下简称"圣湘生物"或"公司"）首次公开发行股票并在科创板上市的 保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票 上市规则（2025 年 4 月修订）》《上市公司募集资金监管规则》和《上海证券交 易所上市公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》等相关 规定，对圣湘生物本次使用部分暂时闲置募集资金进行现金管理的事项进行了审 慎核查，具体核查情况如下： 二、募集资金投资项目情况 根据公司《首次公开发行股票并在科创板上市招股说明书》，公司本次发行 新股的实际募集资金扣除发行费用后的净额将全部用于与公司主营业务相关的 1 由于募集资金投资项目建设及款项的结算与支付需要一定周期，根据合同约 定的付款进度安排，部分项目尾款尚未达到支付时点，公司的部分募集资金存在 暂时闲置的情形。 三、使用部分暂时闲置募集资金进行现金管理的相关情况 （一）本次使用部分暂时闲置募集资金进行现金管理的基本情况 1、投资目 ...

湖南启元律师事务所 关于圣湘生物科技股份有限公司 2025 年限制性股票激励计划授予相关事项的 法律意见书 2025 年 8 月 致：圣湘生物科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受圣湘生物科技股份有限公司 （以下简称"公司""圣湘生物"）的委托，作为公司2025年限制性股票激励计 划项目（以下简称"本次激励计划""激励计划"）专项法律顾问，为公司本次 激励计划提供专项法律服务。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）及中国证券监督管理委员会 （以下简称"中国证监会"）发布的《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、上海证券交易所发布的《科创板上市公司自律监管指南第 4号--股权激励信息披露》（以下简称"《监管指南》"）、《上海证券交易所 科创板股票上市规则》（以下简称"《上市规则》"）等现行法律、法规和规范 性文件以及《圣湘生物科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，就公司 本次激励计划出具本法律意见书。 本所（含经办 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-052 圣湘生物科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日召开第三届 董事会 2025 年第一次临时会议，审议通过了《圣湘生物科技股份有限公司关于使用 部分暂时闲置募集资金进行现金管理的议案》，同意以合计不超过人民币 13,000.00 万 元的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好的投资产品，该 额度自公司前次募集资金现金管理的授权到期之日（即 2025 年 8 月 15 日）起 12 个 月内有效，在上述期限内可以滚动使用。董事会授权董事长在经批准的额度、投资的 产品品种和决议有效期限内决定拟购买的具体产品并签署相关合同文件，具体执行事 项由公司财务部负责组织实施。保荐人西部证券股份有限公司对上述事项出具了明确 的核查意见。本事项无需提交股东大会审议。 一、募集资金基本情况 根据中国证券监督 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-054 圣湘生物科技股份有限公司 关于完成董事会换届选举暨聘任高级管理人员及 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）于 2025 年 7 月 29 日召开 2025 年第三次临时股东会，并于同日召开职工代表大会，选举产生了公 司第三届董事会成员。2025 年 8 月 5 日，公司召开第三届董事会 2025 年第一次临时 会议，选举产生了第三届董事会董事长、专门委员会委员，并聘任了新一届高级管理 人员及证券事务代表。现将相关情况公告如下： 一、董事会换届选举情况 （一）董事换届选举情况 2025 年 7 月 29 日，公司召开 2025 年第三次临时股东会，采用累积投票制选举戴 立忠先生、彭铸先生、卫哲先生、鲁凤民先生、王海啸先生、吴康先生担任公司第三 届董事会非独立董事，选举王善平先生、肖朝君先生、李堂先生、马骥先生担任公司 第三届董事会独立董事。同日，公司召开职工代表大会 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-055 圣湘生物科技股份有限公司 第三届董事会 2025 年第一次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 圣湘生物科技股份有限公司（以下简称"公司"）第三届董事会 2025 年第一次 临时会议于 2025 年 8 月 5 日以现场结合通讯方式召开，会议通知已于 2025 年 8 月 1 日以邮件方式送达全体董事。第三届董事会全体董事推举董事戴立忠先生主持会议， 应出席董事 11 人，实际出席董事 11 人。会议的通知、召开及审议程序符合《中华人 民共和国公司法》（以下简称"《公司法》"）和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，一致通过如下议案： 1、审议通过了《圣湘生物科技股份有限公司关于选举公司第三届董事会各专门 委员会委员的议案》 内容：公司第三届董事会各专门委员会的具体组成如下： （1）战略委员会：戴立忠（主任委员）、马骥、肖朝君； （2）审计委员会：王善平（主任委员）、肖朝君 ...

Market Overview - The pharmaceutical and biotechnology index increased by 2.95%, outperforming the CSI 300 index by 4.70 percentage points and the ChiNext index by 3.23 percentage points, ranking first among 31 sub-industries [4] - The Hong Kong Hang Seng Medical Health Index rose by 1.87%, surpassing the Hang Seng Index by 5.65 percentage points [4] Company R&D Progress Tracking - Recent clinical application submissions include Yimeng Biotech's DB-1419 and Hengrui Medicine's SHR-7782 injection [5] - Haisco's HSK39004 inhalation powder has also initiated its IND application [5] - Ongoing Phase III clinical trials are being conducted for Shiyao Group's SYHX1901 and Hengrui Medicine's SHR-1905, while Hengrui's HRS-7249 is in Phase II, and Kaiyin Technology's KW-040 is in Phase I [5] Current Insights - The outbreak of Chikungunya fever in Foshan has prompted the local government to initiate a Level III public health emergency response, with over 6,000 confirmed cases reported [6] - Several listed companies, including Da'an Gene, Wanfu Biology, and Shengxiang Biology, have developed PCR-based testing solutions for Chikungunya fever [6] - High-throughput sequencing solutions have been introduced by BGI and Dian Diagnostics, while antigen-antibody testing solutions are provided by companies like Aotai Biology and Rejing Biology [6] - This outbreak is expected to accelerate the accumulation of clinical data for related testing products and expedite their market approval [6] 2025 Annual Investment Strategy - The investment strategy emphasizes the need for structural selection of investment opportunities due to complex changes in population structure, policy frameworks, and economic environments [7] - The core contradiction lies in the willingness and ability to pay, leading to a focus on three payment channels within the pharmaceutical industry: hospital payments, out-of-pocket payments, and overseas payments [7] - Key investment directions include policy support for hospital payments (innovative drugs and devices), expansion of public demand (blood products, home medical devices, weight loss drug industry), and an upward cycle for overseas payments (heparin, respiratory joint inspections) [7]

Core Insights - The merger and acquisition (M&A) activity in the Sci-Tech Innovation Board has significantly increased in 2023, with over 50 new transactions disclosed, indicating a vibrant market [1][2] - The introduction of policies such as the "Eight Guidelines" and "Six Guidelines" has effectively stimulated the M&A market, leading to over 110 disclosed equity acquisition transactions since the "Eight Guidelines" were released [1][2] - The focus of M&A activities is primarily on strategic emerging industries, particularly in high-tech sectors like new generation information technology, biomedicine, and high-end equipment manufacturing [1][2] Summary by Sections M&A Activity and Policy Impact - The Sci-Tech Innovation Board has seen a notable rise in M&A transactions, with 35 significant cash acquisitions and share-based mergers reported since the "Eight Guidelines" were introduced, surpassing the total of 17 from 2019 to 2023 [1] - The proportion of cash acquisitions and share-based mergers among the 50 new transactions since 2025 is 40% [1] Industry Focus and Integration - The new M&A transactions are heavily concentrated in high-tech industries, with 21 in new generation information technology, 6 in biomedicine, and 5 in high-end equipment manufacturing [1] - Notable industry consolidation examples include Huahai Chengke's acquisition of Hengsuo Huawai, which positions the combined entity as the second-largest in the global semiconductor materials sector [1] Market Dynamics and Asset Range - The M&A market is characterized by a focus on industrial mergers, particularly within strategic emerging industries, enhancing resource optimization along the supply chain [2] - The range of acquisition targets has expanded to include unprofitable assets, overseas targets, and companies planning for IPOs, with 30 new acquisitions of unprofitable targets and 14 of overseas targets reported [2] Transaction Efficiency and Payment Methods - Institutional innovations, such as allowing acquisitions of unprofitable assets and streamlining processes, have improved transaction efficiency and directed capital towards hard technology sectors [3] - Diverse payment methods for M&A transactions have emerged, including convertible bonds, private placements, and acquisition loans, enhancing transaction feasibility [3] Market Characteristics and Valuation Innovations - The M&A market has become more market-oriented, showcasing varied valuation levels and pricing arrangements since the introduction of the "Eight Guidelines" [3] - Innovative valuation mechanisms have been observed, such as differentiated pricing based on the cost of entry for different investors and performance-based adjustments in valuations [3] Overall Market Sentiment - The combination of policy innovation and market vitality is revitalizing the M&A landscape in the Sci-Tech Innovation Board, fostering high-quality industrial mergers that support sustainable development [4]

Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

Core Insights - The Shanghai Stock Exchange Science and Technology Innovation Board Medical Index (Sci-Tech Medical Index) reported a value of 807.76 points, showing a low opening and a high closing on August 4 [1] - The Sci-Tech Medical Index has increased by 8.56% over the past month, 13.65% over the past three months, and 11.39% year-to-date [2] Index Composition - The Sci-Tech Medical Index includes no more than 30 listed companies in the medical field from the Sci-Tech Innovation Board, reflecting the overall performance of these securities [2] - The index is based on a starting point of 1000.0 points as of December 30, 2022 [2] - The top ten weighted companies in the index are: - Huatai Medical (9.47%) - United Imaging (9.08%) - Hotgen Biotech (8.33%) - Aibo Medical (6.07%) - Yirui Technology (6.05%) - Nanwei Medical (5.62%) - Xinmai Medical (4.81%) - Shengxiang Biotech (4.6%) - Haier Biomedical (3.76%) - Tianzhihang (3.29%) [2] Market and Sector Breakdown - The Sci-Tech Medical Index is fully composed of companies listed on the Shanghai Stock Exchange [3] - The sector distribution of the index's holdings is as follows: - Medical consumables: 42.88% - Medical devices: 28.80% - In-vitro diagnostics: 28.32% [3] - The index samples are adjusted quarterly, with adjustments occurring in the second Friday of March, June, September, and December [3]